Literature DB >> 19596920

Doxorubicin and congo red effectiveness on prion infectivity in golden Syrian hamster.

Manuel Corato1, Paolo Ogliari, Fabrizio Ceciliani, Emanuela Cova, Vincenzo Bellotti, Cristina Cereda, Giampaolo Merlini, Mauro Ceroni.   

Abstract

The effect of doxorubicin and Congo Red on prion protein (PrP) infectivity in experimental scrapie was studied to better understand the effect of these compounds in prion diseases and to establish whether a dose-response correlation exists for Congo Red. This was performed in order to test the effectiveness of compounds that may easily be used in human prion diseases. Brain homogenate containing membrane bound PrPSc monomers was used as inoculum and was previously incubated with doxorubicin 10(-3) M and with increasing concentrations of Congo Red ranging from 10(-7) to 10(-2) M. This study shows for the first time that doxorubicin, and confirms that Congo Red, may interact with pathological PrP monomers modifying their infectious properties. Pre-incubation of infected brain homogenate with Congo Red resulted in prolonged incubation time and survival, independently of Congo Red concentration (p<0.05). Doxorubicin and Congo Red effects do not depend upon interaction with PrP amyloid material.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19596920

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

Review 1.  Prion-Like Propagation of Post-Translationally Modified Tau in Alzheimer's Disease: A Hypothesis.

Authors:  Shweta Kishor Sonawane; Subashchandrabose Chinnathambi
Journal:  J Mol Neurosci       Date:  2018-07-07       Impact factor: 3.444

2.  Secreted cellular prion protein binds doxorubicin and correlates with anthracycline resistance in breast cancer.

Authors:  Adrian P Wiegmans; Jodi M Saunus; Sunyoung Ham; Richard Lobb; Jamie R Kutasovic; Andrew J Dalley; Mariska Miranda; Caroline Atkinson; Simote T Foliaki; Kaltin Ferguson; Colleen Niland; Cameron N Johnstone; Victoria Lewis; Steven J Collins; Sunil R Lakhani; Fares Al-Ejeh; Andreas Möller
Journal:  JCI Insight       Date:  2019-02-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.